Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rishi Sharma

Gastroenterology Walnut Creek, CA Medical Doctor

NPI 1992969281 CMS profile 363140

2637 Shadelands Dr, Walnut Creek, CA 94598

Open in the dashboard

General payments

$3,862

178 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rishi Sharma of Walnut Creek, CA is reported in the CMS Open Payments database as having received $3,862 across 178 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 61st percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,155 48
2024 General $845 36
2023 General $548 19
2022 General $374 25
2021 General $616 39
2020 General $12 1
2019 General $312 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rishi Sharma
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Rishi Sharma were reported at $1,155. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Rishi Sharma Gastroenterology median Middle half National median
2019 $312 $417 $126–$1,100 $163
2020 $12 $224 $74–$624 $114
2021 $616 $352 $106–$1,054 $132
2022 $374 $448 $129–$1,270 $149
2023 $548 $533 $150–$1,390 $160
2024 $845 $605 $160–$1,606 $164
2025 $1,155 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,195 48 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $825 56 payments
  3. Janssen Biotech, Inc. $513 20 payments
  4. Boston Scientific Corporation $372 11 payments
  5. Phathom Pharmaceuticals, Inc. $139 4 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $126 6 payments
  7. Celgene Corporation $94 6 payments
  8. Braintree Laboratories, Inc. $89 4 payments
  9. Pfizer Inc. $74 3 payments
  10. Cook Medical LLC $61 1 payment
  11. Other $374 19 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,802 177 payments
  2. Travel and Lodging $60 1 payment
Products named General payments · program years 2019–2025
  1. XIFAXAN $747 52 payments
  2. RINVOQ $475 17 payments
  3. LINZESS $414 20 payments
  4. CREON $394 21 payments
  5. TREMFYA $300 11 payments
  6. SKYRIZI Immunology $228 8 payments
  7. TRULANCE $226 16 payments
  8. STELARA $214 9 payments
  9. SKYRIZI Immunology $205 9 payments
  10. AXIOS $202 3 payments
  11. Other $1,661 77 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

1,768

Median for Gastroenterology: 569

Drug cost

$534,310

Median for Gastroenterology: $104,976

Branded share of claims

36.2%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Stelara Ustekinumab Brand 11 $301,367
Creon Lipase/Protease/Amylase Brand 37 $66,444
Linzess Linaclotide Brand 45 $29,370
Xifaxan Rifaximin Brand 11 $27,334
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 346 $23,522
Mesalamine Generic 25 $15,513
Voquezna Vonoprazan Fumarate Brand 17 $10,637
Budesonide Dr Budesonide Brand 32 $10,365
Dexlansoprazole Dr Dexlansoprazole Brand 43 $9,509
Ursodiol Generic 21 $7,637

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$263,675

Medicare's payments for the services billed

Medicare patients

852

Average age 75

Services billed

2,002

458 women, 394 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 46%
Ischemic heart disease 24%
Osteoporosis 23%
Chronic kidney disease 21%
Diabetes 20%
Depression 19%
Atrial fibrillation 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VOQUEZNA
$114 17 —
XIFAXAN
$100 11 —
ZEPOSIA
$94 — —
TREMFYA
$82 — —
SKYRIZI
$78 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

178 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record